6735-35-9

Basic information

• Product Name: N-(n-Propyl)diethanolamine,[N,N-Bis(2-hydroxyethyl)-n-propylamine]
• Synonyms: 2,2'-(propylimino)bisethanol;N-PropylDiethanolamine(N-Pdea);N-(n-Propyl)diethanolamine;N,N-Bis(2-hydroxyethyl)-n-propylamine;Propyldiethanolamine;N,N-Bis-(2-hydroxyethyl)-propylamine;Einecs 229-786-5;Ethanol, 2,2'-(propylimino)bis-
• CAS NO: 6735-35-9
• Molecular Formula: C₇H₁₇NO₂
• Molecular Weight: 147.21538
• EINECS: 229-786-5
• Product Categories: Amines;Catalysts;Cross Linking Reagents
• Mol File: 6735-35-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 262.7°C at 760 mmHg
• Flash Point: 126.1°C
• Appearance: /
• Density: 1.005g/cm³
• Vapor Pressure: 0.00152mmHg at 25°C
• Refractive Index: 1.475
• CAS DataBase Reference: N-(n-Propyl)diethanolamine,[N,N-Bis(2-hydroxyethyl)-n-propylamine](CAS DataBase Reference)
• NIST Chemistry Reference: N-(n-Propyl)diethanolamine,[N,N-Bis(2-hydroxyethyl)-n-propylamine](6735-35-9)
• EPA Substance Registry System: N-(n-Propyl)diethanolamine,[N,N-Bis(2-hydroxyethyl)-n-propylamine](6735-35-9)

Safety Data

• Hazardous Substances Data: 6735-35-9(Hazardous Substances Data)

Usage

Uses

Free tertiary amine accelerator used as catalyst for the curing of poly(diethylene glycol maleate). N-(n-Propyl)diethanolamine,[N,N-Bis(2-hydroxyethyl)-n-propylamine] is a muscarinic receptor propylbenzilylcholine mustard binding product.

Hazard

N-(n-Propyl)diethanolamine,[N,N-Bis(2-hydroxyethyl)-n-propylamine] is a poison by ingestion and skin contact. A severe eye irritant.

InChI:InChI=1/C7H17NO2/c1-2-3-8(4-6-9)5-7-10/h9-10H,2-7H2,1H3

Upstream product

• 106-94-5 propyl bromide 
• 111-42-2 2,2'-iminobis[ethanol] 
• 75-21-8 oxirane 
• 107-10-8 propylamine 

Downstream Products

• 30824-25-0 N,N-bis<2-(diphenylphosphino)ethyl>-n-propylamine 
• 129992-44-5 N-n-Propyl-N'-(4-pentyloxyphenyl)-piperazine 
• 38521-66-3 bis-(2-chloro-ethyl)-propyl-amine; hydrochloride 
• 621-68-1 bis(2-chloroethyl)propylamine 

Relevant articles and documents

METHOD FOR PRODUCING CIS- AND TRANS-ENRICHED MDACH

A process for preparing trans-enriched MDACH, including: distilling an MDACH starting mixture in the presence of an auxiliary, which is an organic compound having a molar mass of 62 to 500 g/mol, a boiling point at least 5° C. above the boiling point of cis,cis-2,6-diamino-1-methylcyclohexane, and 2 to 4 functional groups, each of which is independently an alcohol group or a primary, secondary or tertiary amino group. The MDACH starting mixture includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, based on the total amount of MDACH present in the MDACH starting mixture. The MDACH starting mixture includes both trans and cis isomers. Trans-enriched MDACH includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, where the proportion of trans isomers in the mixture is higher than the proportion of trans isomers in the MDACH starting mixture.

Synthesis of 2-γ-N-(aminoethyl)aminopropyl-2-methyl-6-alkyl(aryl,H)-1,3-dioxa-6- aza-2-silacyclooctanes

Some new 2-γ-N-(aminoethyl)aminopropyl-2-methyl-1,3-dioxa-6-aza-2- silacyclooctane and 2-γ-N-(aminoethyl)aminopropyl-2-methyl-6-alkyl(aryl)-1,3-dioxa-6-aza- 2-silacyclooctanes have been synthesized from γ-chloropropyldimethoxymethyl silane by ethylenediamine substitution and diethanolamine or N-alkyl(aryl)diethanolamines substitution. The resulting silocanes have been characterized by elemental analyses, IR, and 1H NMR.

Neurochemistry of aging. 1. Toxins for an animal model of Alzheimer's disease

A chronic deficiency in central cholinergic function has been implicated in a number of neuropsychiatric diseases including Alzheimer's disease. Until recently, animal models that simulate the neurochemical conditions that appear to cause these diseases in humans, as a result of a direct manipulation of the central cholinergic system, were not available. Over the past few years, however, we have been successful in developing a cholinotoxin, 1-ethyl-1-(2-hydroxyethyl)aziridinium chloride (AF64A), which has the potential to serve as a novel compound in developing animal models of human brain disorders in which a cholinergic hypofunction has been implicated. In this paper are described the design, synthesis, and testing of several structural analogues of AF64A as potential cholinotoxins, by evaluating them for their ability to inhibit high-affinity choline transport and their affinity toward brain muscarinic receptors. One of the compounds, 1-cyclopropyl-1-(2-hydroxyethyl)aziridinium chloride was found to have a remarkably high affinity (about 40 times higher than AF64A) toward brain muscarinic receptors.